Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults.

Weinberg A, Lambert SL, Canniff J, Yu L, Lang N, Esser MT, Falloon J, Levin MJ.

Hum Vaccin Immunother. 2019;15(10):2466-2474. doi: 10.1080/21645515.2019.1589282. Epub 2019 Jun 3.

PMID:
30852939
2.

Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults.

Ali SO, Yu XQ, Robbie GJ, Wu Y, Shoemaker K, Yu L, DiGiandomenico A, Keller AE, Anude C, Hernandez-Illas M, Bellamy T, Falloon J, Dubovsky F, Jafri HS.

Clin Microbiol Infect. 2019 May;25(5):629.e1-629.e6. doi: 10.1016/j.cmi.2018.08.004. Epub 2018 Aug 11.

3.

Generalized ROC methods for immunogenicity data analysis of vaccine phase I studies in a seropositive population.

Yu L, Esser MT, Falloon J, Villafana T, Yang H.

Hum Vaccin Immunother. 2018;14(11):2692-2700. doi: 10.1080/21645515.2018.1489191. Epub 2018 Jul 12.

4.

An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.

Falloon J, Yu J, Esser MT, Villafana T, Yu L, Dubovsky F, Takas T, Levin MJ, Falsey AR.

J Infect Dis. 2017 Dec 12;216(11):1362-1370. doi: 10.1093/infdis/jix503.

5.

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.

Falloon J, Talbot HK, Curtis C, Ervin J, Krieger D, Dubovsky F, Takas T, Yu J, Yu L, Lambert SL, Villafana T, Esser MT.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00157-17. doi: 10.1128/CVI.00157-17. Print 2017 Sep.

6.

Passive and active immunization against respiratory syncytial virus for the young and old.

Villafana T, Falloon J, Griffin MP, Zhu Q, Esser MT.

Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1333425. Epub 2017 Jun 7. Review.

PMID:
28525961
7.

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.

Falloon J, Ji F, Curtis C, Bart S, Sheldon E, Krieger D, Dubovsky F, Lambert S, Takas T, Villafana T, Esser MT.

Vaccine. 2016 May 27;34(25):2847-54. doi: 10.1016/j.vaccine.2016.04.002. Epub 2016 Apr 19.

8.

Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database.

Kyaw MH, Kern DM, Zhou S, Tunceli O, Jafri HS, Falloon J.

BMC Health Serv Res. 2015 Jun 21;15:241. doi: 10.1186/s12913-015-0917-x.

9.

Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.

Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J.

Expert Rev Vaccines. 2012 Nov;11(11):1293-303. doi: 10.1586/erv.12.108. Epub 2012 Nov 14. Review.

PMID:
23151111
10.

Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.

Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB.

Pediatr Infect Dis J. 2012 Jul;31(7):745-51. doi: 10.1097/INF.0b013e31825687b0.

PMID:
22466322
11.

A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.

Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.

Vaccine. 2011 Nov 21;29(50):9391-7. doi: 10.1016/j.vaccine.2011.09.109. Epub 2011 Oct 6.

PMID:
21983154
12.

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.

Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F; MI-CP149 Investigators.

Pediatr Infect Dis J. 2012 Feb;31(2):109-14. doi: 10.1097/INF.0b013e31823386f1.

PMID:
21926667
13.

A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.

Bernstein DI, Falloon J, Yi T.

Vaccine. 2011 Sep 16;29(40):7042-8. doi: 10.1016/j.vaccine.2011.07.031. Epub 2011 Jul 22.

PMID:
21782874
14.

An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years.

Ambrose CS, Yi T, Falloon J.

Influenza Other Respir Viruses. 2011 Nov;5(6):389-97. doi: 10.1111/j.1750-2659.2011.00243.x. Epub 2011 Apr 4.

15.

Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, Adelsberger JW, Metcalf JA, Polis MA, Kovacs SB, Kovacs JA, Davey RT, Lane HC, Masur H, Sereti I.

Blood. 2008 Jul 15;112(2):287-94. doi: 10.1182/blood-2007-12-127878. Epub 2008 May 2. Erratum in: Blood. 2014 Jul 17;124(3):463. Kovacs, Stephen J [corrected to Kovacs, Stephen B].

16.

Cryptococcosis and idiopathic CD4 lymphocytopenia.

Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE.

Medicine (Baltimore). 2007 Mar;86(2):78-92.

17.

Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7.

Malaspina A, Moir S, Chaitt DG, Rehm CA, Kottilil S, Falloon J, Fauci AS.

Blood. 2007 Mar 1;109(5):2086-8. Epub 2006 Oct 19.

18.

Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.

Robertson SM, Formentini E, Alfaro RM, Falloon J, Penzak SR.

Pharmacotherapy. 2006 Aug;26(8):1051-9.

PMID:
16863481
20.

Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.

Robertson SM, Formentini E, Alfaro RM, Natarajan V, Falloon J, Penzak SR.

Br J Clin Pharmacol. 2006 Apr;61(4):379-88.

21.

Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.

Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, Falloon J, Davey RT Jr, Dewar RL, Metcalf JA, Mellors JW, Coffin JM.

AIDS. 2006 Mar 21;20(5):701-10.

PMID:
16514300
22.

Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.

Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly G, Metcalf JA, Davey RT Jr, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, Bosche M, Issaq HJ, Fox SD, Leitman S, Baseler MW, Masur H, Di Mascio M, Dimitrov DS, Lane HC.

J Clin Invest. 2005 Aug;115(8):2139-48. Epub 2005 Jul 14.

23.

Graves' disease after interleukin-2 therapy in a patient with human immunodeficiency virus infection.

Jimenez C, Moran SA, Sereti I, Wynne S, Yen PM, Falloon J, Davey RT, Sarlis NJ.

Thyroid. 2004 Dec;14(12):1097-102.

PMID:
15650365
24.

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT Jr, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM.

J Clin Microbiol. 2005 Jan;43(1):406-13.

25.

Vaccination in humans generates broad T cell cytokine responses.

De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, Evans TG, Koup R, Miller CJ, Roederer M.

J Immunol. 2004 Nov 1;173(9):5372-80.

26.

Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.

Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J.

Ther Drug Monit. 2004 Jun;26(3):322-30.

PMID:
15167636
27.

A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.

Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT Jr, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC.

J Infect Dis. 2003 Aug 15;188(4):531-6. Epub 2003 Jul 31.

PMID:
12898439
28.

Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.

Polis MA, Suzman DL, Yoder CP, Shen JM, Mican JM, Dewar RL, Metcalf JA, Falloon J, Davey RT Jr, Kovacs JA, Feinberg MB, Masur H, Piscitelli SC.

AIDS. 2003 May 23;17(8):1167-72.

PMID:
12819518
29.

Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover.

Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, Falloon J, Polis MA, Lane HC, Sereti I.

J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):125-33.

PMID:
12794543
30.

HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.

Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M; CNA2007 International Study Team.

Antivir Ther. 2003 Apr;8(2):111-20.

PMID:
12741623
31.

High prevalence of osteonecrosis of the femoral head in HIV-infected adults.

Miller KD, Masur H, Jones EC, Joe GO, Rick ME, Kelly GG, Mican JM, Liu S, Gerber LH, Blackwelder WC, Falloon J, Davey RT, Polis MA, Walker RE, Lane HC, Kovacs JA.

Ann Intern Med. 2002 Jul 2;137(1):17-25.

PMID:
12093241
32.

Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.

Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J.

Pharmacotherapy. 2002 May;22(5):551-6.

PMID:
12013352
33.

Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings.

Kopp JB, Falloon J, Filie A, Abati A, King C, Hortin GL, Mican JM, Vaughan E, Miller KD.

Clin Infect Dis. 2002 Apr 15;34(8):1122-8. Epub 2002 Mar 15.

PMID:
11915002
34.

HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.

Falloon J, Ait-Khaled M, Thomas DA, Brosgart CL, Eron JJ Jr, Feinberg J, Flanigan TP, Hammer SM, Kraus PW, Murphy R, Torres R, Masur H; CNA2007 Study Team.

AIDS. 2002 Feb 15;16(3):387-96.

PMID:
11834950
35.

Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS, Lane HC.

J Exp Med. 2001 Dec 17;194(12):1731-41.

36.

The effect of garlic supplements on the pharmacokinetics of saquinavir.

Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J.

Clin Infect Dis. 2002 Jan 15;34(2):234-8. Epub 2001 Dec 5.

PMID:
11740713
37.

Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.

Kovacs JA, Vogel S, Metcalf JA, Baseler M, Stevens R, Adelsberger J, Lempicki R, Hengel RL, Sereti I, Lambert L, Dewar RL, Davey RT Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC.

Eur J Immunol. 2001 May;31(5):1351-60.

38.

A potential role for interleukin-7 in T-cell homeostasis.

Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, Steinberg SM, Wood LV, Yarchoan R, Zuckerman J, Landay A, Mackall CL.

Blood. 2001 May 15;97(10):2983-90.

PMID:
11342421
39.

Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion.

Miller KD, Spooner K, Herpin BR, Rock-Kress D, Metcalf JA, Davey RT Jr, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Lane HC.

Clin Immunol. 2001 Apr;99(1):30-42.

PMID:
11286539
40.

Salvage antiretroviral therapy.

Falloon J.

AIDS. 2000;14 Suppl 3:S209-17. Review. No abstract available.

PMID:
11086864
42.

Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression.

Orenstein JM, Bhat N, Yoder C, Fox C, Polis MA, Metcalf JA, Kovacs JA, Falloon J, Walker RE, Masur H, Lane HC, Davey RT.

AIDS. 2000 Aug 18;14(12):1709-15.

PMID:
10985306
43.

Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression.

Kovacs JA, Imamichi H, Vogel S, Metcalf JA, Dewar RL, Baseler M, Stevens R, Adelsberger J, Lambert L, Davey RT Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC.

J Infect Dis. 2000 Oct;182(4):1063-9. Epub 2000 Sep 5.

PMID:
10979900
44.

Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT Jr, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC.

Blood. 2000 Jul 15;96(2):467-74.

PMID:
10887107
45.

Indinavir concentrations and St John's wort.

Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J.

Lancet. 2000 Feb 12;355(9203):547-8. Erratum in: Lancet 2001 Apr 14;357(9263):1210.

PMID:
10683007
46.

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.

Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H.

Clin Infect Dis. 2000 Feb;30(2):313-8.

PMID:
10671334
47.

High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.

Imamichi T, Sinha T, Imamichi H, Zhang YM, Metcalf JA, Falloon J, Lane HC.

J Virol. 2000 Jan;74(2):1023-8.

48.

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, Lane HC.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14.

49.

Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study.

Falloon J, Sargent S, Piscitelli SC, Bechtel C, LaFon SW, Sadler B, Walker RE, Kovacs JA, Polis MA, Davey RT Jr, Lane HC, Masur H.

Pharmacotherapy. 1999 Sep;19(9):1050-6.

PMID:
10610011
50.

Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.

Whitcup SM, Fortin E, Lindblad AS, Griffiths P, Metcalf JA, Robinson MR, Manischewitz J, Baird B, Perry C, Kidd IM, Vrabec T, Davey RT Jr, Falloon J, Walker RE, Kovacs JA, Lane HC, Nussenblatt RB, Smith J, Masur H, Polis MA.

JAMA. 1999 Nov 3;282(17):1633-7.

PMID:
10553789

Supplemental Content

Loading ...
Support Center